Prevention and Treatment of Patient Before, During, and After Covid-19 Infection (AntiCov-220)

Nguyen Thi Trieu, MD

Status and phase: Completed; Phase 2

Conditions: Covid19

Treatments: Drug: AntiCov-220 (2); Drug: AntiCov-220 (1)

Study type: Interventional

Identifiers

NCT05043324

COVID-19 and Immunodeficiency

Details and patient eligibility

About

AntiCov-220 prevents and treats before, during, and after infection with SARS-Cov-2. The composition is fractionally extracted from herbs, using flavonoids, isoflavonoids, and pregnenolone in combination with ascorbic acid as the key compounds in preventing and killing SARS-CoV-2; increase antibodies and protect cells; supplementing precursors to help the body strengthen antibodies and reduce the risk of infection; destroy spike protein, toxic protein, help prevent blood clots causing stroke; restore the physiological function of cells after virus infection; helps the body to stabilize the amount of cortisol in the blood as well as stabilize the production of specific antibodies. The composition participates in anti-inflammatory and cells protecting process, bringing blood cortisol, B-lymphocytes, Cyfra 21-1, WBC, CRP, fever, dyspnea, and other signs of respiratory tract inflammation to a normal state and normal limit.

Full description

AntiCov-220 can eliminate COVID-19 and its variants at a very early stage when they have not had enough time to multiply and cause disease. AntiCov-220 contains precursors, flavonoids, special enzymes responsible for protecting human cell membranes and destroying cell membranes of some viruses, especially, COVID-19 cannot replicate in the presence of AntiCov-220 in the body.

AntiCov-220 contains precursors of cortisol. As the investigators know, cortisol has a cell anti-inflammatory, blood pressure regulation, blood sugar regulation, energy booster, and anti-stress role. It provides precursors to help direct and balance the amount of cortisol in the body that has been imbalanced before.

AntiCov-220 contains flavonoids and Isoflavonoids that are cytoprotective antioxidants, clinically proven to destroy SARS-CoV-2, HBV, HIV, HCV, viruses, reduce complications after COVID-19 infection, prevent neurological sequelae, stroke, cardiovascular sequelae, respiratory sequelae, ...

The anti-inflammatory, stress-reducing, cell-protective, anti-viral, and immunosuppressive process are performed by an in vivo method that has proven its effectiveness more than ten years ago. AntiCov-220 is an innovative product that can fight against COVID-19 and its variants in the current epidemic situation.

AntiCov-220 is committed to protecting the community of people infected with HBV, HIV, HCV, SARS-CoV-2 against the risk of the COVID-19 pandemic and its mutations.

AntiCov-220 easy to implement, highly effective, and helps reduce public health costs, which is essential in protecting human health.

AntiCov-220 can be used alongside with current standard treatment regimens prescribed by the World Health Organization.

Enrollment: 82 patients

Sex: All

Ages: 16 to 82 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• All patients with underlying medical conditions who have been taking medications for these conditions.
• Patients with AIDS, HIV, HBV, HCV, and patients with co-infections.
• The cancer patients are stable.
• Patients with congenital or acquired immunodeficiency.

Exclusion criteria

• Unstable cancer patients.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

82 participants in 2 patient groups

SARS-COV-2 (1)

Experimental group

Description:

Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (1) for various therapeutic purposes.

Treatment:

Drug: AntiCov-220 (1)

SARS-COV-2 (2)

Experimental group

Description:

Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (2) for various therapeutic purposes.

Treatment:

Drug: AntiCov-220 (2)